Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 11Pemetrexed 10pembrolizumab 9Nivolumab 3LMB-100 3budigalimab 2belinostat 2amatuximab 2Paclitaxel 2Docetaxel 2Dexamethasone 2Cyclophosphamide 2Carboplatin 2Calcium Dobesilate 2venetoclax 1trametinib 1tislelizumab 1tazemetostat 1talazoparib 1spartalizumab 1sodium thiosulfate 1sargramostim 1ruxolitinib 1rovalpituzumab tesirine 1olaparib 1obinutuzumab 1naptumomab estafenatox 1irinotecan sucrosofate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mesothelioma × CB-839 × Clear all
NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡